诱导多能干细胞

iPSCs 在 BCMA 靶向治疗多发性骨髓瘤中的现状与前景

The Current Landscape and Prospects of iPSCs in BCMA-targeted Therapy for Multiple Myeloma.

多发性骨髓瘤（MM）是一种难以治疗的血浆细胞恶性肿瘤，其发病机制具有异质性，预后较差。

障碍与蓝图：胃肠道肿瘤中 CAR-T 细胞治疗的下一代工程策略

Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.

近期开展的CT041-ST-01 II期试验评估了satricabtagene autoleucel，这是首个在实体瘤中进行的随机CAR-T 试验，结果显示晚期胃癌患者的PFS显著改善（中位3.25 vs.

癌症之外的 CAR 工程化细胞治疗：重编程纤维化和免疫介导炎症

CAR-Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune-Mediated Inflammation.

iPSC 来源 CAR-NK 细胞外囊泡治疗非小细胞肺癌：证据、工程化改造与转化障碍

iPSC-derived CAR-NK extracellular vesicles for non-small cell lung cancer: evidence, engineering, and translational barriers.

工程化机械敏感 MSC 实现跨瘤种的合成放射诊疗靶向

Engineered mechanosensitive MSCs enable synthetic radiotheranostic targeting across tumor types.

通过 LDHB 进行的代谢重编程赋予 hiPSC 来源 NK 细胞对乳酸诱导的功能障碍的抗性并增强抗肿瘤活性

Metabolic reprogramming via LDHB confers resistance to lactate-induced dysfunction and enhanced antitumor activity in hiPSC-Derived NK cells.

iPSC 衍生多价疫苗作为具个体发育学信息依据的免疫原以克服微卫星稳定型结直肠癌的免疫难治性：癌症免疫治疗的新兴前沿

iPSC-derived polyvalent vaccines as ontogenetically informed immunogens toward overcoming immune refractoriness in microsatellite-stable colorectal ca

推进胶质母细胞瘤 CAR-T 细胞疗法前沿：从临床障碍到突破性策略的现状探索

Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough s

基于快速尸检骨与肝转移灶的致死性神经内分泌前列腺癌整合临床前平台

An Integrated Preclinical Platform for Lethal Neuroendocrine Prostate Cancer from Rapid Autopsy Bone and Liver Metastases.

异基因 iPSC 来源 γδT 细胞对患者来源组织显示抗肿瘤疗效

Allogeneic iPSC-derived γδT cells demonstrate antitumor efficacy against patient-derived tissues.